ReviewDigestive diseases and sciences2023
Diagnosis and Management of Hepatitis Delta Virus Infection.
Review in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The Prevalence and Risk Factors of Hepatitis B, Hepatitis C, and Hepatitis D Coinfection in Iran's General Population Over the Past 25 Years: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2025Pooled it
- Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.Hepatology communications · 2026Trial
- Hepatitis B and D burden in Uzbekistan: comprehensive analysis of seroprevalence and risk correlates from a countrywide study.Infectious diseases of poverty · 2026Article
- FDA approval of hepcludex: a milestone in the treatment of chronic hepatitis delta virus infection.Annals of medicine and surgery (2012) · 2026Article
- Improvement in the Microbiological Diagnosis of Hepatitis D on the Mediterranean Coast of Southeastern Spain: A Repeated Cross-Sectional Survey.Health science reports · 2026Article
- Review
- Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States.Journal of viral hepatitis · 2026Article
- Molecular characterization of bat HBV and identification of HDV co-infection in Yunnan, China.Frontiers in microbiology · 2026Article
- Double reflex testing for anti-HDV antibody following an HBsAg-positive test result and HDV RNA in those anti-HDV positive: a global systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Development and External Validation of an Algorithm for Identifying HDV RNA-Positive Patients.Gastro hep advances · 2026Article
- TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.Hepatology (Baltimore, Md.) · 2025Article
- Article
- Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- The Seroprevalence, Risk Factors, and Clinical Profile of Hepatitis D in Omani Patients with Chronic Hepatitis B: A Multicenter Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2025Review
- Proteins and peptides as antigen candidates for the immunodiagnosis of hepatitis D.Amino acids · 2025Review
- Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs.World journal of virology · 2025Review
- Article
- A universal point-of-care immunochromatographic test for the serodiagnosis of hepatitis D.Journal of clinical microbiology · 2025Article
- Investigation of Hepatitis C, D, and HIV Seroprevalence and Evaluation of APRI and FIB-4 Scores in HbsAg-Positive Patients.Viruses · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D virus (HDV) depends on hepatitis B virus (HBV) to enter and exit hepatocytes and to replicate. Despite this dependency, HDV can cause severe liver disease. HDV accelerates liver fibrosis, increases the risk of hepatocellular carcinoma, and hastens hepatic decompensation compared to chronic HBV monoinfection. The Chronic Liver Disease Foundation (CLDF) formed an expert panel to publish updated guidelines on the testing, diagnosis, and management of hepatitis delta virus. The panel group performed network data review on the transmission, epidemiology, natural history, and disease sequelae of acute and chronic HDV infection. Based on current available evidence, we provide recommendations for screening, testing, diagnosis, and treatment of hepatitis D infection and review upcoming novel agents that may expand treatment options. The CLDF recommends universal HDV screening for all patients who are Hepatitis B surface antigen-positive. Initial screening should be with an assay to detect antibodies generated against HDV (anti-HDV). Patients who are positive for anti-HDV IgG antibodies should then undergo quantitative HDV RNA testing. We also provide an algorithm that describes CLDF recommendations on the screening, diagnosis, testing, and initial management of Hepatitis D infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.